Geneos Wealth Management Inc. Has $5.05 Million Stock Position in Stryker Co. (NYSE:SYK)

Geneos Wealth Management Inc. increased its holdings in shares of Stryker Co. (NYSE:SYK) by 0.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 14,018 shares of the medical technology company’s stock after acquiring an additional 92 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Stryker were worth $5,047,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Zhang Financial LLC increased its stake in Stryker by 55.0% during the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock worth $41,366,000 after purchasing an additional 40,784 shares in the last quarter. Dale Q Rice Investment Management Ltd acquired a new stake in shares of Stryker during the fourth quarter worth $587,000. PFW Advisors LLC bought a new stake in Stryker in the 4th quarter valued at $1,350,000. Parnassus Investments LLC acquired a new position in Stryker in the 3rd quarter worth $762,798,000. Finally, Baltimore Washington Financial Advisors Inc. raised its stake in shares of Stryker by 2.4% in the 3rd quarter. Baltimore Washington Financial Advisors Inc. now owns 66,681 shares of the medical technology company’s stock valued at $24,089,000 after purchasing an additional 1,554 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on SYK shares. Needham & Company LLC reiterated a “buy” rating and set a $442.00 price objective on shares of Stryker in a report on Tuesday, January 7th. JPMorgan Chase & Co. boosted their price objective on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Barclays lifted their price target on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. UBS Group raised their price objective on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Finally, StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a research report on Wednesday. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average target price of $405.80.

Stryker Stock Up 0.1 %

Shares of SYK opened at $394.08 on Friday. The firm’s 50-day simple moving average is $376.11 and its 200 day simple moving average is $360.81. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm has a market cap of $150.23 billion, a P/E ratio of 42.24, a price-to-earnings-growth ratio of 2.68 and a beta of 0.95. Stryker Co. has a 52 week low of $307.23 and a 52 week high of $398.20.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.46 earnings per share. On average, analysts forecast that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date is Tuesday, December 31st. This is a boost from Stryker’s previous quarterly dividend of $0.80. Stryker’s payout ratio is presently 36.01%.

Insider Activity at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. 5.90% of the stock is currently owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.